APA (7th ed.) Citation

Charles-Schoeman, C., Zueger, P., McDearmon-Blondell, E., Fang, S., Peng, Y., Oishi, T., . . . Tesser, J. (2026). Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States. Rheumatology & Therapy, 13(1), 95. https://doi.org/10.1007/s40744-025-00808-z

Chicago Style (17th ed.) Citation

Charles-Schoeman, Christina, Patrick Zueger, Erin McDearmon-Blondell, Siran Fang, Yi Peng, Tanjinatus Oishi, Manish Jain, and John Tesser. "Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States." Rheumatology & Therapy 13, no. 1 (2026): 95. https://doi.org/10.1007/s40744-025-00808-z.

MLA (9th ed.) Citation

Charles-Schoeman, Christina, et al. "Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States." Rheumatology & Therapy, vol. 13, no. 1, 2026, p. 95, https://doi.org/10.1007/s40744-025-00808-z.